Do GLP-1–Based Therapies Increase Cancer Risk?
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
Cases of pancreatitis have been de-scribed in connection with the useof exenatide (1), liraglutide (2) and other glucagon-like peptide (GLP)-1 re-ceptor agonists. From these findings, the following hypothesis has been generated: stimulating the GLP-1 receptor with re-spective agonists has a potential to cause pancreatitis, perhaps chronic pancreati-tis, and in the long term, potentially even pancreatic cancer (3–5). Further-more, in rodents like mice and rats, stim-ulating the GLP-1 receptor raises cAMP in thyroid C cells, initiates the release of cal-citonin, and upon longer-term exposure, is accompanied by C-cell proliferation and the formation of C-cell adenomas
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, there is evidence that GLP-1 analogues increase the risk of medullary thyroid cancer, which is a cause for concern.268”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [268]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“For the purpose of this review, GLP-1–based therapies are GLP-1 receptor agonists such as exenatide, liraglutide, and others or dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin (8).”
BackgroundSelf-citationVincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62307-0 · Cited by 2,586
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502 · cited 1×
“It takes another 7 years (approximately) for such cells to develop subclones with metastatic capacity and another 3 years (approximately) before the disease will be diagnosed due to clinical symptoms and a clinically apparent primary tumor accompanied by metastases (13).”
BackgroundUnder-Reporting of Adverse Drug Reactions: A Systematic Review
Hazell, L., & Shakir, S. A. W. (2006) · Drug Safety · doi:10.2165/00002018-200629050-00003 · Cited by 1,931
Pancreatitis and the Risk of Pancreatic Cancer
Lowenfels, A. B., Maisonneuve, P., Cavallini, G., Ammann, R. W., Lankisch, P. G., Andersen, J. R., Dimagno, E. P., Andren-Sandberg, A., & Domellof, L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305203282001 · Cited by 1,757
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 8×
“(3), we looked at subcategories of malignant disease entities.”
BackgroundMethodInfluentialBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 5×
“C-cell disease ranges from C-cell hyperplasia to C-cell adenoma and medullary carcinoma (6).”
BackgroundInfluentialDeterminants of Under-Reporting of Adverse Drug Reactions: A Systematic Review
Lopez-Gonzalez, E., Herdeiro, M. T., & Figueiras, A. (2009) · Drug Safety · doi:10.2165/00002018-200932010-00002 · Cited by 574
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 1×
“In mice and rats, a once-daily injection of liraglutide, a GLP-1 receptor agonist that has an approximate half-life of 13 h, leads to permanently elevated circulating drug concentrations (32,33) and increased rate of C-cell abnormalities in both mice and rats, with some animals developing C-cell carcinomas, especially…”
BackgroundThyroid Cancer Incidence Patterns in the United States by Histologic Type, 1992–2006
Aschebrook-Kilfoy, B., Ward, M. H., Sabra, M. M., & Devesa, S. S. (2011) · Thyroid · doi:10.1089/thy.2010.0021 · Cited by 454
Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392
Self-citationHypoglycemia in patients with type 2 diabetes mellitus
Miller, C. D., Phillips, L. S., Ziemer, D. C., Gallina, D. L., Cook, C. B., & El-Kebbi, I. M. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.13.1653 · Cited by 341
Dore, D. D., Seeger, J. D., & Arnold Chan, K. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902820519 · Cited by 326 · cited 2×
“Results from pharmacoepidmiological analyses, which have typically been based on claims databases, indicate that the population of obese type 2 diabetic patients is at higher risk of developing acute pancreatitis and that the relative risk is approximately twoto threefold higher than in nonobese control populations (2…”
BackgroundAcute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Garg, R., Chen, W., & Pendergrass, M. (2010) · Diabetes Care · doi:10.2337/dc10-0482 · Cited by 322
Elbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L. B., Rolan, P., Sturis, J., Hatorp, V., & Zdravkovic, M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1398 · Cited by 279 · cited 1×
“In mice and rats, a once-daily injection of liraglutide, a GLP-1 receptor agonist that has an approximate half-life of 13 h, leads to permanently elevated circulating drug concentrations (32,33) and increased rate of C-cell abnormalities in both mice and rats, with some animals developing C-cell carcinomas, especially…”
BackgroundGier, B., Matveyenko, A. V., Kirakossian, D., Dawson, D., Dry, S. M., & Butler, P. C. (2012) · Diabetes · doi:10.2337/db11-1109 · Cited by 255
Matveyenko, A. V., Dry, S., Cox, H. I., Moshtaghian, A., Gurlo, T., Galasso, R., Butler, A. E., & Butler, P. C. (2009) · Diabetes · doi:10.2337/db09-0058 · Cited by 242 · cited 2×
“(14) described an area of pancreatitis in one of the HIP rats treated with sitagliptin and in none of the other groups.”
BackgroundHegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2318 · Cited by 194 · cited 1×
“8 mg daily (patients with type 2 diabetes) with no systematic change in calcitonin concentrations indicating any measurable response to GLP-1 receptor stimulation (34).”
BackgroundBiochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
Nachnani, J. S., Bulchandani, D. G., Nookala, A., Herndon, B., Molteni, A., Pandya, P., Taylor, R., Quinn, T., Weide, L., & Alba, L. M. (2010) · Diabetologia · doi:10.1007/s00125-009-1515-4 · Cited by 189 · cited 1×
“(16) found higher degrees of exocrine pancreatic inflammation after treatment with exendin4, with a significantly increased number of pyknotic nuclei, but just a trend toward more fibrosis.”
BackgroundHartnell, N. R., & Wilson, J. P. (2004) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.8.743.36068 · Cited by 172
Strobel, O., Rosow, D. E., Rakhlin, E. Y., Lauwers, G. Y., Trainor, A. G., Alsina, J., Fernández–Del Castillo, C., Warshaw, A. L., & Thayer, S. P. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.005 · Cited by 168
Koehler, J. A., Baggio, L. L., Lamont, B. J., Ali, S., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db09-0626 · Cited by 159 · cited 1×
“(18) described a change toward a less inflammatory state in animals treated with GLP-1 receptor agonists.”
BackgroundGlucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland
Gier, B., Butler, P. C., Lai, C. K., Kirakossian, D., DeNicola, M. M., & Yeh, M. W. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2407 · Cited by 157
Engel, S. S., Williams-Herman, D. E., Golm, G. T., Clay, R. J., Machotka, S. V., Kaufman, K. D., & Goldstein, B. J. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02382.x · Cited by 144
A cohort study of acute pancreatitis in relation to exenatide use
Dore, D. D., Bloomgren, G. L., Wenten, M., Hoffman, C., Clifford, C. R., Quinn, S. G., Braun, D. K., Noel, R. A., & Seeger, J. D. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01376.x · Cited by 144
van der Heijden, P. G. M., van Puijenbroek, E. P., van Buuren, S., & van der Hofstede, J. W. (2002) · Statistics in Medicine · doi:10.1002/sim.1157 · Cited by 135
The Human GLP-1 Analog Liraglutide and the Pancreas
Nyborg, N. C. B., Mølck, A.-M., Madsen, L. W., & Bjerre Knudsen, L. (2012) · Diabetes · doi:10.2337/db11-0936 · Cited by 125 · cited 1×
“Cases of pancreatitis have been described in connection with the use of exenatide (1), liraglutide (2) and other glucagon-like peptide (GLP)-1 receptor agonists.”
BackgroundExenatide and rare adverse events.
Ahmad, S. R., & Swann, J. (2008) · PubMed · Cited by 122
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Price, D. L., Chen, R., Udell, J., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.08.006 · Cited by 106
Tatarkiewicz, K., Smith, P. A., Sablan, E. J., Polizzi, C. J., Aumann, D. E., Villescaz, C., Hargrove, D. M., Gedulin, B. R., Lu, M. G. W., Adams, L., et al. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00479.2010 · Cited by 91 · cited 1×
“In these studies, the administration of exenatide before the induction of experimental acute pancreatitis using cerulein reduced the increments in amylase or lipase activity (17).”
MethodSystematic review and meta-analysis of insulin therapy and risk of cancer
Janghorbani, M., Dehghani, M., & Salehi-Marzijarani, M. (2012) · Hormones and Cancer · doi:10.1007/s12672-012-0112-z · Cited by 86 · cited 1×
“This additional sensitivity analysis was performed because of the well-known tumor-promoting potential of insulin (42,43).”
BackgroundAddressing the issue of channeling bias in observational studies with propensity scores analysis
Lobo, F. S., Wagner, S., Gross, C. R., & Schommer, J. C. (2006) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2005.12.001 · Cited by 83
Waser, B., Beetschen, K., Pellegata, N. S., & Reubi, J. C. (2011) · Neuroendocrinology · doi:10.1159/000330447 · Cited by 80 · cited 1×
“Another recent study using an evenmore specific method to detect (and rule out) GLP-1 receptors in tissues (a radioligand assay) did not confirmGLP-1 receptors in human thyroid tissue outside C cells (35).”
ResultWenten, M., Gaebler, J. A., Hussein, M., Pelletier, E. M., Smith, D. B., Girase, P., Noel, R. A., Braun, D. K., & Bloomgren, G. L. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03652.x · Cited by 75
Bhanot, U. K., & Möller, P. (2009) · Laboratory Investigation · doi:10.1038/labinvest.2009.19 · Cited by 75
Wolfe, F., Flowers, N., Burke, T. A., Arguelles, L., & Pettitt, D. (2002) · PubMed · Cited by 73
Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?
Butler, P. C., Matveyenko, A. V., Dry, S., Bhushan, A., & Elashoff, R. (2010) · Diabetologia · doi:10.1007/s00125-009-1591-5 · Cited by 69
A potential competition bias in the detection of safety signals from spontaneous reporting databases
Pariente, A., Didailler, M., Avillach, P., Miremont‐Salamé, G., Fourrier‐Reglat, A., Haramburu, F., & Moore, N. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2022 · Cited by 66
Goodman, M. J., & Nordin, J. (2006) · PEDIATRICS · doi:10.1542/peds.2004-2687 · Cited by 65
Koehler, J. A., & Drucker, D. J. (2006) · Diabetes · doi:10.2337/db05-1145 · Cited by 60 · cited 1×
“Furthermore, the same authors studied the effects of GLP-1 receptor stimulation on the proliferation of human pancreatic adenomcarcinoma cell lines and found no growth-promoting effects (19).”
BackgroundForrow, S., Campion, D. M., Herrinton, L. J., Nair, V. P., Robb, M. A., Wilson, M., & Platt, R. G. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2242 · Cited by 58 · cited 1×
“Food and Drug Administration (FDA), which will allow better postmarketing surveillance regarding rare adverse events of novel drugs (29,30).”
BackgroundMcAdams‐DeMarco, M., Governale, L. A., Swartz, L., Hammad, T. A., & Pan, G. J. D. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1633 · Cited by 56
GLP-1–Based Therapies: The Dilemma of Uncertainty
Spranger, J., Gundert‐Remy, U., & Stammschulte, T. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.05.019 · Cited by 49 · cited 1×
“It raised the question of whether the FDA Adverse Event Reporting System is a suitable database for reaching solid conclusions regarding the incidence of certain adverse events related to drug treatment (36).”
BackgroundEdholm, T., Čejvan, K., Abdel‐Halim, S. M., Efendić, S., Schmidt, P., & Hellström, P. M. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01229.x · Cited by 33
GLP-1: Broadening the incretin concept to involve gut motility
Hellström, P. M. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.04.004 · Cited by 30
Weng, C., Bigger, J. T., Busacca, L., Wilcox, A. B., & Getaneh, A. (2010) · PubMed Central · Cited by 27
Steinberg, W. M., DeVries, J. H., Wadden, T. A., Jensen, C. B., Svendsen, C. B., & Rosenstock, J. (2012) · Gastroenterology · doi:10.1016/s0016-5085(12)63296-x · Cited by 26
Local appendiceal dysbiosis: the missing link between the appendix and ulcerative colitis?
Roblin, X., Neut, C., Darfeuille–Michaud, A., & Colombel, J. (2011) · Gut · doi:10.1136/gutjnl-2011-300576 · Cited by 26
(2012) · Diabetes · doi:10.2337/db12-er08 · Cited by 23
Riddle, M. S., & Porter, C. K. (2011) · Gut · doi:10.1136/gutjnl-2011-300617 · Cited by 22
Simeone, J. C., & Quilliam, B. J. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q352 · Cited by 20
Insulin therapy and cancer risk in diabetes mellitus
Platts, J. K. (2010) · Clinical Medicine · doi:10.7861/clinmedicine.10-5-509 · Cited by 13
Mullard, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3713 · Cited by 9 · cited 1×
“Food and Drug Administration (FDA), which will allow better postmarketing surveillance regarding rare adverse events of novel drugs (29,30).”
BackgroundOne year of sitagliptin treatment does not result in exocrine pancreatic pathology in mice
Hull, R. L., Aston‐Mourney, K., Subramanian, S. L., & Goldstein, L. C. (2011) · Cited by 1
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“When GLP-1 RAs were introduced as novel agents to treat type 2 diabetes, there was uncertainty about several potential adverse effects such as acute pancreatitis, pancreatic cancer, and thyroid cancer [102,103].”
BackgroundSelf-citationBethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
“Detailed discussions of pancreatitis potentially induced by DPP-4 inhibitors have been published [51,52].”
BackgroundSelf-citationGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
“Acute pancreatitis may potentially progress to chronic pancreatitis and ultimately develop pancreatic cancer (Yachida et al., 2010; Nauck and Friedrich, 2013).”
BackgroundMethod
Metadata
- Authors
- Nauck, M. A., & Friedrich, N.
- Affiliations
- Diabeteszentrum Bad Lauterberg (DE)
- Universität Greifswald (DE)
- Corresponding author
- Friedrich, Nele
- ORCID
- Nauck, Michael A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-07-17
- Volume
- 36
- Issue
- Supplement_2
- Pages
- S245-S252
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3920789
- OpenAlex
- W2158762809
- Cited by
- 145
- References
- 56
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 10 · 2023: 8 · 2022: 10 · 2021: 12 · 2020: 10 · 2019: 8 · 2018: 7 · 2017: 17 · 2016: 12 · 2015: 13 · 2014: 17 · 2013: 2
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- GLP-1 receptor agonists, exenatide, liraglutide, pancreatitis, chronic pancreatitis, pancreatic cancer, thyroid C cells, calcitonin, cAMP signaling, cancer risk
- MeSH terms
- Animals, Drug Therapy, Combination, Humans, Hypoglycemic Agents, Pancreatic Neoplasms, Pancreatitis, Risk Factors, Thyroid Neoplasms, Glucagon-Like Peptide 1, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.